A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate the Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Physicians interested in becoming principal investigators please contact
- Email: clinical_inquiry_hub@lilly.com
Study Contact Backup
- Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 317-615-4559
- Email: LillyTrials@Lilly.com
Study Locations
-
-
-
Ahmedabad, India, 380006
- V.S. General Hospital
-
Ahmedabad, India, 380 016
- B. J. Medical College & Civil Hospital
-
Ahmedabad, India, 380052
- Gujarat Endocrine Center
-
Ajmer, India, 305001
- Jawahar Lal Nehru Medical College
-
Allahābād, India, 211002
- Motilal Nehru Medical College Hospital
-
Bengaluru, India, 560092
- Lifecare Hospital and Research Centre
-
Bhubaneswar, India, 751019
- AIIMS, Bhubaneshwar
-
Chennai, India, 600116
- Sri Ramachandra MedicaL College & Research Institute
-
Coimbatore, India, 641009
- Kovai Diabetes Speciality Center and Hospital
-
Guwahati, India, 781033
- Apollo Excelcare Hospital
-
Hyderabad, India, 500012
- Osmania Medical College & Hospital
-
Jaipur, India, 302017
- Eternal Heart Care Center and Research Institute
-
Kanpur, India, 208001
- K care Hospital
-
Kanpur, India, 208020
- Brij Medical Centre Private Limited
-
Kolkata, India, 700064
- ILS Hospitals
-
Kozhikode, India, 673008
- Government Medical College, Kozhikode
-
Mumbai, India, 400011
- Wockhardt Hospitals
-
Nagpur, India, 440012
- Shri Krishna Hrudayalaya & Critical Care Centre
-
Pune, India, 411004
- Sahyadri Super Speciality Hospital
-
Raipur, India, 492099
- All India Institute of Medical Sciences
-
Visakhapatnam, India, 530002
- King George Hospital, Andhra Medical College
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants with Type 2 Diabetes:
- Have had type 2 diabetes for at least one year
- Insulin naive
- Have HbA1c ≥7.5% and ≤10% at screening
- Have body mass index (BMI) ≥23 kilograms per square meter (kg/m2)
Participants with Obesity or Overweight without Type 2 Diabetes:
Have a BMI
- Greater than or equal to 30 kg/m2 OR
- Greater than or equal to 27 kg/m2 AND previously diagnosed with at least one of the following weight-related comorbidities: high blood pressure, lipid disorder, obstructive sleep apnea, heart disease
Exclusion Criteria:
Participants with Type 2 Diabetes:
- Have type 1 diabetes
Have had any of the following heart conditions within 6 months prior to screening:
- heart attack
- stroke
- hospitalization due to heart failure
- Have New York Heart Association Functional Classification Class III or IV congestive heart failure (CHF)
- Have type 2 diabetes along with morbid obesity and being considered for bariatric surgery or any other procedure intended for weight loss
Participants with Obesity or Overweight without Type 2 Diabetes:
- Have type 1 diabetes or type 2 diabetes
- Have a self-reported change in body weight greater than 5 kilograms (kg) (11 pounds) within 3 months prior to screening
- Have a prior or planned surgical treatment for obesity
Have had any of the following heart conditions within 6 months prior to screening:
- heart attack
- stroke
- hospitalization due to heart failure
- Have New York Heart Association Functional Classification Class III or IV CHF
- Have taken any medications or alternative remedies for weight loss within 3 months prior to screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tirzepatide
Participants will receive tirzepatide subcutaneously (SC)
|
Administered SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Time Frame: Baseline through Week 46
|
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
|
Baseline through Week 46
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants with ≥5% Body Weight Reduction
Time Frame: Week 46
|
Week 46
|
|
Percentage of Participants with Hemoglobin A1c (HbA1c) <7.0% in Participants with Type 2 Diabetes
Time Frame: Week 46
|
Week 46
|
|
Change from Baseline in Waist Circumference in Participants with Obesity or Overweight
Time Frame: Baseline, Week 46
|
Baseline, Week 46
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Overweight
- Obesity
- Diabetes Mellitus, Type 2
- Amino Acids, Peptides, and Proteins
- Proteins
- Glucagon-Like Peptide-1 Receptor
- Glucagon-Like Peptide Receptors
- Receptors, G-Protein-Coupled
- Receptors, Cell Surface
- Membrane Proteins
- Receptors, Gastrointestinal Hormone
- Receptors, Peptide
- Tirzepatide
Other Study ID Numbers
Other Study ID Numbers
- 27235
- I8F-IN-GPIZ (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.